Published • loading... • Updated
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?
Summary by The Motley Fool
1 Articles
1 Articles
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?
Key PointsEli Lilly currently leads the weight loss market. Novo Nordisk's newer launches could help it make up some ground.Both could capitalize on the growing anti-obesity market, but one of them looks more attractive. 10 stocks we like better than Eli Lilly › Analysts project that the weight loss market will grow rapidly in the coming years. Investors looking to cash in on this may turn to the companies that lead this niche: Eli Lilly (NYSE: …
·Alexandria, United States
Read Full Article
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
